Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G N Lam

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Pharmacology|January 1, 1996
Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartanP C Wong, D D Christ, Y N Wong, et al.
Journal of Chromatography. B, Biomedical Applications|March 4, 1994
Determination of a novel sigma receptor antagonist, DuP 734, in rat plasma by reversed-phase high-performance liquid chromatography with ultraviolet detectionR P Kapil, W Lee, N Y Wong, et al.
Journal of Chromatography. B, Biomedical Applications|March 10, 1995
Determination of a novel cognitive enhancer, X9121, and its mono N-oxide metabolite, XG696, in dog plasma by reversed-phase high-performance liquid chromatography with ultraviolet detectionR P Kapil, W Lee, P K Padovani, et al.
Thrombosis Research|May 1, 1997
Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogsR P Kapil, T A Emm, S A Mousa, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1994
The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dogD D Christ, P C Wong, Y N Wong, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor XaJ M Fevig, J Cacciola, R S Alexander, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 1999
Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor XaJ M Fevig, J Buriak, P F Stouten, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 1, 1996
Pharmacokinetics and metabolism of EXP921, a novel cognitive enhancer, in ratsY N Wong, C Y Quon, K A Holm, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 5, 2004
Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy menA R van Troostenburg, D Lee, T R Jones, et al.
British Journal of Cancer|May 18, 2006
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumoursM E Cianfrocca, K A Kimmel, J Gallo, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Pharmacology|January 1, 1996
Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartanP C Wong, D D Christ, Y N Wong, et al.
Journal of Chromatography. B, Biomedical Applications|March 4, 1994
Determination of a novel sigma receptor antagonist, DuP 734, in rat plasma by reversed-phase high-performance liquid chromatography with ultraviolet detectionR P Kapil, W Lee, N Y Wong, et al.
Journal of Chromatography. B, Biomedical Applications|March 10, 1995
Determination of a novel cognitive enhancer, X9121, and its mono N-oxide metabolite, XG696, in dog plasma by reversed-phase high-performance liquid chromatography with ultraviolet detectionR P Kapil, W Lee, P K Padovani, et al.
Thrombosis Research|May 1, 1997
Biological matrix-dependent pharmacokinetic and pharmacodynamic parameters of a novel platelet glycoprotein IIB/IIIA receptor antagonist, XU063, in beagle dogsR P Kapil, T A Emm, S A Mousa, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 1994
The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dogD D Christ, P C Wong, Y N Wong, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Preparation of meta-amidino-N,N-disubstituted anilines as potent inhibitors of coagulation factor XaJ M Fevig, J Cacciola, R S Alexander, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 1999
Preparation of pyrrolidine and isoxazolidine benzamidines as potent inhibitors of coagulation factor XaJ M Fevig, J Buriak, P F Stouten, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 1, 1996
Pharmacokinetics and metabolism of EXP921, a novel cognitive enhancer, in ratsY N Wong, C Y Quon, K A Holm, et al.
International Journal of Clinical Pharmacology and Therapeutics|June 5, 2004
Safety, tolerability and pharmacokinetics of subcutaneous A6, an 8-amino acid peptide with anti-angiogenic properties, in healthy menA R van Troostenburg, D Lee, T R Jones, et al.
British Journal of Cancer|May 18, 2006
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumoursM E Cianfrocca, K A Kimmel, J Gallo, et al.
Pageof 3